UNICREDIT BANK/PUT/AMGEN/300/0.1/18.09.24 | Real-time BOERSE MUENCHEN 16:40:40 17/06/2024 BST | ||
| 1.15 EUR | -10.16% |
|
| Current month | +12.28% | ||
| 1 month | +28.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 17/06/24 | 1.15 | -10.16% |
| 14/06/24 | 1.28 | +0.79% |
| 13/06/24 | 1.27 | +6.72% |
| 12/06/24 | 1.19 | -0.83% |
| 11/06/24 | 1.2 | +10.09% |
Real-time BOERSE MUENCHEN
Last update June 17, 2024 at 04:40 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | AMGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD03KT |
| ISIN | DE000HD03KT7 |
| Date issued | 23/10/2023 |
| Strike | 300 $ |
| Maturity | 18/09/2024 (93 Days) |
| Parity | 10 : 1 |
| Emission price | 3.38 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.99 € |
|---|---|
| Lowest since issue | 0.78 € |
| Spread | 0.02 € |
| Spread % | 1.72% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
298.6
USD
Average target price
316.4
USD
Spread / Average Target
+5.97%
- Stock Market
- Warrants
- Warrant
